Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Eur Respir J

Retrieve available abstracts of 80 articles:
HTML format

Single Articles

    May 2024
  1. CAVERLY LJ, Ross BD, Dickson RP
    From gut to lung and back again: early life microbiota in cystic fibrosis.
    Eur Respir J. 2024;63:2400595.

    April 2024
  2. FURSTOVA E, Drevinek P, Novotna S, Libik M, et al
    Precision medicine in cystic fibrosis: predictive role of forskolin-induced swelling assay.
    Eur Respir J. 2024;63:2400156.

    March 2024
  3. FRAYMAN KB, Macowan M, Caparros-Martin J, Ranganathan SC, et al
    The Longitudinal Microbial and Metabolic Landscape of infant Cystic Fibrosis: The gut-lung axis.
    Eur Respir J. 2024 Mar 14:2302290. doi: 10.1183/13993003.02290-2023.
    PubMed     Abstract available

    Socioeconomic disparities in European cystic fibrosis outcomes: time to close the gap.
    Eur Respir J. 2024;63:2400328.

  5. XU X, Li JD, Green TJ, Wilson L, et al
    Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis.
    Eur Respir J. 2024;63:2301512.
    PubMed     Abstract available

  6. KEREM E, Orenti A, Adamoli A, Hatziagorou E, et al
    Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain.
    Eur Respir J. 2024;63:2301241.
    PubMed     Abstract available

    Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis.
    Eur Respir J. 2024;63:2400234.

    February 2024
  8. COHEN R, Shteinberg M
    Unravelling the "frequent exacerbator" phenotype in cystic fibrosis.
    Eur Respir J. 2024;63:2400068.

  9. HOUSTON CJ, Alkhatib A, Einarsson GG, Tunney MM, et al
    Diminished airway host innate response in people with cystic fibrosis who experience frequent pulmonary exacerbations.
    Eur Respir J. 2024;63:2301228.
    PubMed     Abstract available

  10. DOONEY M, Saba T
    Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Eur Respir J. 2024;63:2301392.

    Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Eur Respir J. 2024;63:2400233.

    January 2024
  12. BURGEL PR, Sermet-Gaudelus I, Girodon E, Kanaan R, et al
    Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint.
    Eur Respir J. 2024;63:2301959.

    December 2023
  13. SUNDE RB MD PHD, Thorsen J MD PhD, Kim M MSc PhD, Schoos AM MD PhD, et al
    Bacterial Colonization of the Airway in Neonates and Risk of Asthma and Allergy Until Age 18 Years.
    Eur Respir J. 2023 Dec 14:2300471. doi: 10.1183/13993003.00471-2023.
    PubMed     Abstract available

  14. BARRY PJ, Burgel PR
    Cast no shadow: assessing the disease-modifying effects of elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2023;62:2302026.

  15. DAINES CL, Tullis E, Costa S, Linnemann RW, et al
    Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
    Eur Respir J. 2023;62:2202029.
    PubMed     Abstract available

  16. SUCRE JMS, Frank DB
    Having new eyes: MRI for visualisation of pulmonary vascular disease and prediction of bronchopulmonary dysplasia severity.
    Eur Respir J. 2023;62:2302041.

    November 2023
  17. HYSINGER EB, Critser P
    How is preterm birth working out: cardiopulmonary response to exercise in extreme prematurity.
    Eur Respir J. 2023;62:2301787.

    October 2023
  18. WANG KCW, Elliot JG, Saglani S, Donovan GM, et al
    The airway smooth muscle layer is structurally abnormal in low birth weight infants - implications for obstructive disease.
    Eur Respir J. 2023 Oct 12:2301176. doi: 10.1183/13993003.01176-2023.

  19. BEEN JV, Simons SHP, Labrecque JA
    Dexamethasone for preterm infants at risk of bronchopulmonary dysplasia: is timing everything?
    Eur Respir J. 2023;62:2301473.

  20. BEAR C, Ratjen F
    Charting the path to expanded access for CFTR modulator drugs: the nose knows.
    Eur Respir J. 2023;62:2301387.

  21. DREANO E, Burgel PR, Hatton A, Bouazza N, et al
    Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
    Eur Respir J. 2023;62:2300110.
    PubMed     Abstract available

  22. HEBESTREIT H, Thornton CS
    Cystic fibrosis and the cardiovascular system: the unexpected heartache.
    Eur Respir J. 2023;62:2301253.

  23. FROST F, Nazareth D, Fauchier L, Wat D, et al
    Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study.
    Eur Respir J. 2023;62:2300174.
    PubMed     Abstract available

    September 2023
  24. DELFRATE J, Girard-Bock C, Curnier D, Perie D, et al
    Cardiopulmonary response to exercise in adults born very preterm.
    Eur Respir J. 2023 Sep 21:2300503. doi: 10.1183/13993003.00503-2023.
    PubMed     Abstract available

  25. HAFNER F, Kindt A, Strobl K, Forster K, et al
    MRI pulmonary artery flow detects lung vascular pathology in preterms with lung disease.
    Eur Respir J. 2023 Sep 7:2202445. doi: 10.1183/13993003.02445-2022.
    PubMed     Abstract available

  26. MORRISON L, Thornton CS
    Quality over quantity: the next ACT in airway clearance in cystic fibrosis.
    Eur Respir J. 2023;62:2301354.

  27. FILIPOW N, Stanojevic S, Raywood E, Shannon H, et al
    Real-world effectiveness of airway clearance techniques in children with cystic fibrosis.
    Eur Respir J. 2023;62:2300522.
    PubMed     Abstract available

    August 2023
  28. KWOK TC, Szatkowski L, Sharkey D
    Impact of postnatal dexamethasone timing on preterm mortality and bronchopulmonary dysplasia: a propensity score analysis.
    Eur Respir J. 2023 Aug 17:2300825. doi: 10.1183/13993003.00825-2023.
    PubMed     Abstract available

  29. POWELL WT, Reeves SR
    From small to big, using microRNA profiling to investigate infant origins of childhood asthma.
    Eur Respir J. 2023;62:2301052.

  30. TUNNEY MM, Wark P
    Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist.
    Eur Respir J. 2023;62:2301008.

  31. SCHAUPP L, Addante A, Voller M, Fentker K, et al
    Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.
    Eur Respir J. 2023;62:2202153.
    PubMed     Abstract available

    July 2023
    More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice.
    Eur Respir J. 2023;62:2300865.

  33. BAYFIELD KJ, Weinheimer O, Boyton C, Fitzpatrick R, et al
    Implementation and evaluation of ultra-low dose CT in early cystic fibrosis lung disease.
    Eur Respir J. 2023;62:2300286.
    PubMed     Abstract available

  34. DWYER TJ, Elkins MR, Dentice R, Forbes S, et al
    Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9% versus 3% versus 6% nebulised saline.
    Eur Respir J. 2023;62:2100960.
    PubMed     Abstract available

    June 2023
  35. ZHU Z, Freishtat RJ, Harmon B, Hahn A, et al
    Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: A multicenter prospective study.
    Eur Respir J. 2023 Jun 15:2300502. doi: 10.1183/13993003.00502-2023.
    PubMed     Abstract available

  36. DUIJTS L
    Prematurity-related chronic respiratory disease across the life course.
    Eur Respir J. 2023;61:2300662.

    May 2023
  37. BEHR J
    The art of clinical trial design in pulmonary fibrosis.
    Eur Respir J. 2023;61:2300346.

  38. May Podcast: Cystic fibrosis.
    Eur Respir J. 2023;61:23E6105.

  39. ADDANTE A, Raymond W, Gitlin I, Charbit A, et al
    A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases.
    Eur Respir J. 2023;61:2202022.
    PubMed     Abstract available

    April 2023
    The effects of elexafactor/tezafactor/ivacaftor beyond the epithelium: spurring macrophages to fight infections.
    Eur Respir J. 2023;61:2300216.

  41. CAVINATO L, Luly FR, Pastore V, Chiappetta D, et al
    Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.
    Eur Respir J. 2023;61:2200725.
    PubMed     Abstract available

  42. ZHANG S, Shrestha CL, Robledo-Avila F, Jaganathan D, et al
    Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2023;61:2102861.
    PubMed     Abstract available

  43. VAN TONDER AJ, Ellis HC, Churchward CP, Kumar K, et al
    M ycobacterium avium complex genomics and transmission in a London hospital.
    Eur Respir J. 2023;61:2201237.
    PubMed     Abstract available

    March 2023
  44. PULAKKA A, Risnes K, Metsala J, Alenius S, et al
    Preterm birth and asthma and COPD in adulthood: a nationwide register study from two Nordic countries.
    Eur Respir J. 2023 Mar 29:2201763. doi: 10.1183/13993003.01763-2022.
    PubMed     Abstract available

    Children and TB pharmacokinetics: no longer in infancy?
    Eur Respir J. 2023;61:2202003.

  46. ASMUS E, Karle W, Brack MC, Wittig C, et al
    Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients.
    Eur Respir J. 2023;61:2202009.
    PubMed     Abstract available

    February 2023
  47. PEDERSEN ESL, Kuehni CE
    Preventing bronchiolitis among infants with non-pharmaceutical interventions outside pandemics: is it realistic?
    Eur Respir J. 2023;61:2202214.

    January 2023
  48. DHOTE T, Martin C, Regard L, Pesenti L, et al
    Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis.
    Eur Respir J. 2023;61:2202096.

    December 2022
  49. RINGSHAUSEN FC, Sauer-Heilborn A, Buttner T, Dittrich AM, et al
    Lung transplantation for end-stage cystic fibrosis before and after the accessibility of elexacaftor/tezacaftor/ivacaftor, Germany, 2012-2021.
    Eur Respir J. 2022 Dec 14:2201402. doi: 10.1183/13993003.01402-2022.

  50. MITROPOULOU G, Brandenberg N, Hoehnel S, Ceroni C, et al
    Rectal organoid-guided CFTR modulator therapy restores lung function in a cystic fibrosis patient with the rare 1677delTA/R334W genotype.
    Eur Respir J. 2022;60:2201341.

    November 2022
  51. WILLERS CC, Frauchiger BS, Stranzinger E, Bauman G, et al
    Feasibility of unsedated lung MRI in young children with cystic fibrosis.
    Eur Respir J. 2022;60.

    September 2022
  52. BONADIES L, Papi A, Baraldi E
    Is bronchopulmonary dysplasia in adult age a novel COPD endotype?
    Eur Respir J. 2022;60.

  53. UM-BERGSTROM P, Pourbazargan M, Brundin B, Strom M, et al
    Increased cytotoxic T-cells in the airways of adults with former bronchopulmonary dysplasia.
    Eur Respir J. 2022;60.
    PubMed     Abstract available

    August 2022
    A step forward for an intermediate cystic fibrosis population.
    Eur Respir J. 2022;60.

  55. NGUYEN-KHOA T, Hatton A, Drummond D, Aoust L, et al
    Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test.
    Eur Respir J. 2022;60.

  56. SAFERALI A, Qiao D, Kim W, Raraigh K, et al
    C FTR variants are associated with chronic bronchitis in smokers.
    Eur Respir J. 2022;60.
    PubMed     Abstract available

  57. MUILWIJK D, de Poel E, van Mourik P, Suen SWF, et al
    Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.
    Eur Respir J. 2022;60.
    PubMed     Abstract available

    July 2022
  58. MURPHY VE, Jensen ME, Holliday EG, Giles WB, et al
    Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00298-2022.
    PubMed     Abstract available

  59. CHASSAGNON G, Campredon A, Vakalopoulou M, Burgel PR, et al
    Diversity of approaches in artificial intelligence: an opportunity for discoveries in thoracic imaging.
    Eur Respir J. 2022;60.

  60. ZHANG B, Zhang S
    Radiomics-derived morphological features predict pulmonary function response during lumacaftor/ivacaftor therapy in patients with cystic fibrosis.
    Eur Respir J. 2022;60.

    May 2022
  61. RIGAUTS C, Aizawa J, Taylor SL, Rogers GB, et al
    R othia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease.
    Eur Respir J. 2022;59.
    PubMed     Abstract available

    March 2022
  62. ZANNIN E, Rigotti C, Neumann RP, Dellaca RL, et al
    Oscillatory mechanics at 36 weeks post-menstrual age as markers of lung disease in preterm infants: a cohort study.
    Eur Respir J. 2022 Mar 2. pii: 13993003.03023-2021.

  63. KURZ JM, Ramsey KA, Rodriguez R, Spycher B, et al
    Association of lung clearance index with survival in individuals with cystic fibrosis.
    Eur Respir J. 2022;59.
    PubMed     Abstract available

    February 2022
  64. YEH HI, Hwang TC
    In vitro assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis.
    Eur Respir J. 2022;59.

  65. HIRANI D, Alvira CM, Danopoulos S, Milla C, et al
    Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia.
    Eur Respir J. 2022;59.
    PubMed     Abstract available

  66. GOSS CH, Fajac I, Jain R, Seibold W, et al
    Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study.
    Eur Respir J. 2022;59.
    PubMed     Abstract available

  67. MORRISON CB, Shaffer KM, Araba KC, Markovetz MR, et al
    Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration.
    Eur Respir J. 2022;59.
    PubMed     Abstract available

    December 2021
  68. RAITA Y, Perez-Losada M, Freishtat RJ, Hahn A, et al
    Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study.
    Eur Respir J. 2021 Dec 16. pii: 13993003.02293-2021.
    PubMed     Abstract available

  69. GURDENIZ G, Ernst M, Rago D, Kim M, et al
    Neonatal metabolome of cesarean section and risk of childhood asthma.
    Eur Respir J. 2021 Dec 9. pii: 13993003.02406-2021.
    PubMed     Abstract available

  70. KRUIZINGA MD, Essers E, Stuurman FE, Yavuz Y, et al
    Clinical validation of digital biomarkers for pediatric patients with asthma and cystic fibrosis - Potential for clinical trials and clinical care.
    Eur Respir J. 2021 Dec 9. pii: 13993003.00208-2021.
    PubMed     Abstract available

    Primary nasal epithelial cells from patients with cystic fibrosis hold promise for guiding precision medicine and expanding treatment.
    Eur Respir J. 2021;58.

  72. SETTE G, Lo Cicero S, Blacona G, Pierandrei S, et al
    Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells.
    Eur Respir J. 2021;58.
    PubMed     Abstract available

    November 2021
  73. BINGLE CD, Bingle L
    SPLUNC1 comes of age? Predicting acute exacerbations in cystic fibrosis.
    Eur Respir J. 2021;58.

  74. KHANAL S, Webster M, Niu N, Zielonka J, et al
    SPLUNC1: a novel marker of cystic fibrosis exacerbations.
    Eur Respir J. 2021;58.
    PubMed     Abstract available

    October 2021
  75. SATRELL E, Clemm H, Roksund O, Hufthammer KO, et al
    Development of lung diffusion to adulthood following extremely preterm birth.
    Eur Respir J. 2021 Oct 8. pii: 13993003.04103-2020.
    PubMed     Abstract available

    September 2021
  76. HART K, Cousins M, Watkins WJ, Kotecha SJ, et al
    Association of Early Life Factors with Prematurity-Associated Lung Disease: Prospective Cohort Study.
    Eur Respir J. 2021 Sep 29. pii: 13993003.01766-2021.
    PubMed     Abstract available

  77. MARTIN C, Burgel PR
    Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries.
    Eur Respir J. 2021;58.

  78. MCKONE EF, Ariti C, Jackson A, Zolin A, et al
    Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study.
    Eur Respir J. 2021;58.
    PubMed     Abstract available

    July 2021
  79. WECKMANN M, Bahmer T, Bulow Sand JM, Rank Ronnow S, et al
    COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy.
    Eur Respir J. 2021 Jul 29. pii: 13993003.03969-2020.
    PubMed     Abstract available

    June 2021
  80. CORIATI A, Sykes J, Lemonnier L, Ma X, et al
    The impact of the high emergency lung transplantation program in cystic fibrosis in France: insight from a comparison with Canada.
    Eur Respir J. 2021 Jun 17. pii: 13993003.00014-2021.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Neonatology is free of charge.